Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter.

After months spent drafting comfortably in Amgen’s KRAS-blocking wake, the time has finally come for Mirati Therapeutics to show its own work. Up until now, Amgen has done all the heavy lifting when it comes to showcasing clinical data on drugs targeting KRAS, the buzzy cancer protein once thought to be “undruggable” because of its spherical structure. Does Mirati have a better KRAS-blocking drug, or not? The first opportunity to compare the rival KRAS drugs comes on Oct. 28, when Mirati is expected to present its first clinical data at a cancer conference.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Adam
    As a Stat subscriber, just wondering, should we take Anavex Life Sciences seriously? Any update on Adaptive Therapeutics or Alector or Guardant Health ?
    Thank you. Enjoy your column.

Your daily dose of news in health and medicine

Privacy Policy